A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Nov 24

PMID 33227941

Citations 2

Authors

Ahmed Abdullah Ahmed

Stephen Neidle

Affiliations

Soon will be listed here.

Abstract

The stabilisation of G-quadruplexes (G4s) by small-molecule compounds is an effective approach for causing cell growth arrest, followed by cell death. Some of these compounds are currently being developed for the treatment of human cancers. We have previously developed a substituted naphthalene diimide G4-binding molecule (CM03) with selective potency for pancreatic cancer cells, including gemcitabine-resistant cells. We report here that CM03 and the histone deacetylase (HDAC) inhibitor SAHA (suberanilohydroxamic acid) have synergistic effects at concentrations close to and below their individual GI values, in both gemcitabine-sensitive and resistant pancreatic cancer cell lines. Immunoblot analysis showed elevated levels of γ-H2AX and cleaved PARP proteins upon drug combination treatment, indicating increased levels of DNA damage (double-strand break events: DSBs) and apoptosis induction, respectively. We propose that the mechanism of synergy involves SAHA relaxing condensed chromatin, resulting in higher levels of G4 formation. In turn, CM03 can stabilise a greater number of G4s, leading to the downregulation of more G4-containing genes as well as a higher incidence of DSBs due to torsional strain on DNA and chromatin structure.

Citing Articles

The histone deacetylase inhibitor Scriptaid targets G-quadruplexes.

Sanchez-Martin V, Ruzic D, Tello-Lopez M, Ortiz-Morales A, Murciano-Calles J, Soriano M Open Biol. 2025; 15(2):240183.

PMID: 39965659 PMC: 11835489. DOI: 10.1098/rsob.240183.

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.

Jo J, Jung D, Lee H, Park S, Chung M, Park J Int J Cancer. 2022; 151(9):1565-1577.

PMID: 35657348 PMC: 9545559. DOI: 10.1002/ijc.34144.

G-quadruplexes: a promising target for cancer therapy.

Kosiol N, Juranek S, Brossart P, Heine A, Paeschke K Mol Cancer. 2021; 20(1):40.

PMID: 33632214 PMC: 7905668. DOI: 10.1186/s12943-021-01328-4.

References

Marchetti C, Zyner K, Ohnmacht S, Robson M, Haider S, Morton J . Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. J Med Chem. 2018; 61(6):2500-2517. PMC: 5867665. DOI: 10.1021/acs.jmedchem.7b01781. View

Ahmed A, Marchetti C, Ohnmacht S, Neidle S . A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells. Sci Rep. 2020; 10(1):12192. PMC: 7376204. DOI: 10.1038/s41598-020-68944-w. View

Burger A, Dai F, Schultes C, Reszka A, Moore M, Double J . The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005; 65(4):1489-96. DOI: 10.1158/0008-5472.CAN-04-2910. View

Sengupta A, Ganguly A, Chowdhury S . Promise of G-Quadruplex Structure Binding Ligands as Epigenetic Modifiers with Anti-Cancer Effects. Molecules. 2019; 24(3). PMC: 6384772. DOI: 10.3390/molecules24030582. View

Ahmed A, Angell R, Oxenford S, Worthington J, Williams N, Barton N . Asymmetrically Substituted Quadruplex-Binding Naphthalene Diimide Showing Potent Activity in Pancreatic Cancer Models. ACS Med Chem Lett. 2020; 11(8):1634-1644. PMC: 7429975. DOI: 10.1021/acsmedchemlett.0c00317. View

Hassell K . Histone Deacetylases and their Inhibitors in Cancer Epigenetics. Diseases. 2019; 7(4). PMC: 6955926. DOI: 10.3390/diseases7040057. View

Mizrahi J, Surana R, Valle J, Shroff R . Pancreatic cancer. Lancet. 2020; 395(10242):2008-2020. DOI: 10.1016/S0140-6736(20)30974-0. View

Gunaratnam M, Green C, Moreira J, Moorhouse A, Kelland L, Moses J . G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo. Biochem Pharmacol. 2009; 78(2):115-22. DOI: 10.1016/j.bcp.2009.03.018. View

Gowan S, Harrison J, Patterson L, Valenti M, Read M, Neidle S . A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol. 2002; 61(5):1154-62. DOI: 10.1124/mol.61.5.1154. View

10.

Porru M, Zizza P, Franceschin M, Leonetti C, Biroccio A . EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochim Biophys Acta Gen Subj. 2016; 1861(5 Pt B):1362-1370. DOI: 10.1016/j.bbagen.2016.11.010. View

11.

Ohnmacht S, Marchetti C, Gunaratnam M, Besser R, Haider S, Di Vita G . A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer. Sci Rep. 2015; 5:11385. PMC: 4468576. DOI: 10.1038/srep11385. View

12.

Phatak P, Cookson J, Dai F, Smith V, Gartenhaus R, Stevens M . Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer. 2007; 96(8):1223-33. PMC: 2360152. DOI: 10.1038/sj.bjc.6603691. View

13.

Bugaut A, Balasubramanian S . 5'-UTR RNA G-quadruplexes: translation regulation and targeting. Nucleic Acids Res. 2012; 40(11):4727-41. PMC: 3367173. DOI: 10.1093/nar/gks068. View

14.

Reina C, Cavalieri V . Epigenetic Modulation of Chromatin States and Gene Expression by G-Quadruplex Structures. Int J Mol Sci. 2020; 21(11). PMC: 7312119. DOI: 10.3390/ijms21114172. View

15.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

16.

Collie G, Promontorio R, Hampel S, Micco M, Neidle S, Parkinson G . Structural basis for telomeric G-quadruplex targeting by naphthalene diimide ligands. J Am Chem Soc. 2012; 134(5):2723-31. DOI: 10.1021/ja2102423. View

17.

Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N . Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer. 2007; 121(3):656-65. DOI: 10.1002/ijc.22558. View

18.

Hansel-Hertsch R, Simeone A, Shea A, Hui W, Zyner K, Marsico G . Landscape of G-quadruplex DNA structural regions in breast cancer. Nat Genet. 2020; 52(9):878-883. DOI: 10.1038/s41588-020-0672-8. View

19.

Chen Z, Qin Q, Qin J, Zhou J, Li Y, Li N . Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell.... J Med Chem. 2015; 58(11):4771-89. DOI: 10.1021/acs.jmedchem.5b00444. View

20.

Nakanishi C, Seimiya H . G-quadruplex in cancer biology and drug discovery. Biochem Biophys Res Commun. 2020; 531(1):45-50. DOI: 10.1016/j.bbrc.2020.03.178. View